Paratek Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.21
- Today's High:
- $2.22
- Open Price:
- $2.21
- 52W Low:
- $1.29
- 52W High:
- $3.65
- Prev. Close:
- $2.21
- Volume:
- 248546
Company Statistics
- Market Cap.:
- $126.68 million
- Book Value:
- -3.515
- Revenue TTM:
- $177.00 million
- Operating Margin TTM:
- -25.17%
- Gross Profit TTM:
- $99.39 million
- Profit Margin:
- -35.44%
- Return on Assets TTM:
- -17.99%
- Return on Equity TTM:
- 0%
Company Profile
Paratek Pharmaceuticals Inc had its IPO on 2006-05-11 under the ticker symbol PRTK.
The company operates in the Healthcare sector and Biotechnology industry. Paratek Pharmaceuticals Inc has a staff strength of 268 employees.
Stock update
Shares of Paratek Pharmaceuticals Inc opened at $2.21 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.21 - $2.22, and closed at $2.21.
This is a 0% increase from the previous day's closing price.
A total volume of 248,546 shares were traded at the close of the day’s session.
In the last one week, shares of Paratek Pharmaceuticals Inc have increased by +0.91%.
Paratek Pharmaceuticals Inc's Key Ratios
Paratek Pharmaceuticals Inc has a market cap of $126.68 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.8558.
In the last 12-months Paratek Pharmaceuticals Inc’s revenue was $177.00 million with a gross profit of $99.39 million and an EBITDA of $-44237000. The EBITDA ratio measures Paratek Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Paratek Pharmaceuticals Inc’s operating margin was -25.17% while its return on assets stood at -17.99% with a return of equity of 0%.
In Q2, Paratek Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 34.9%.
Paratek Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 1.7206
- Trailing PE
- 0
- PEG
- -0.02
Its diluted EPS in the last 12-months stands at $-1.11 per share while it has a forward price to earnings multiple of 1.7206 and a PEG multiple of -0.02. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Paratek Pharmaceuticals Inc’s profitability.
Paratek Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2.868 and a EV to EBITDA ratio of -4.4262. Its price to sales ratio in the trailing 12-months stood at 0.8558.
Paratek Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $145.79 million
- Total Liabilities
- $202.62 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Paratek Pharmaceuticals Inc ended 2024 with $145.79 million in total assets and $0 in total liabilities. Its intangible assets were valued at $145.79 million while shareholder equity stood at $-201365000.00.
Paratek Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $202.62 million in other current liabilities, 57000.00 in common stock, $-965145000.00 in retained earnings and $829000.00 in goodwill. Its cash balance stood at $42.69 million and cash and short-term investments were $42.69 million. The company’s total short-term debt was $164,042,000 while long-term debt stood at $94.29 million.
Paratek Pharmaceuticals Inc’s total current assets stands at $105.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $42.51 million compared to accounts payable of $2.95 million and inventory worth $11.41 million.
In 2024, Paratek Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Paratek Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.21
- 52-Week High
- $3.65
- 52-Week Low
- $1.29
- Analyst Target Price
- $3.1
Paratek Pharmaceuticals Inc stock is currently trading at $2.21 per share. It touched a 52-week high of $3.65 and a 52-week low of $3.65. Analysts tracking the stock have a 12-month average target price of $3.1.
Its 50-day moving average was $2.2 and 200-day moving average was $2.06 The short ratio stood at 6.98 indicating a short percent outstanding of 0%.
Around 1170% of the company’s stock are held by insiders while 5508.4% are held by institutions.
Frequently Asked Questions About Paratek Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.